Dynorphin (2-17), Amide, Porcine Mechanisms, Clinical Applic

Dynorphin (2-17), Amide, Porcine: Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Dynorphin (2-17), amide, porcine, is a synthetic peptide fragment derived from the endogenous opioid peptide dynorphin A, specifically encompassing amino acids 2 through 17 of the parent sequence. As a member of the dynorphin family, this peptide is characterized by its interaction with opioid receptors, particularly the kappa-opioid receptor (KOR), and is notable for its role in modulating nociception, neuroprotection, and neurodegeneration (Chavkin et al., 1982, Science). The amide modification at the C-terminus enhances its stability and bioactivity, making it a valuable research tool in neuropharmacology and pain research.

Dynorphin peptides are produced from the precursor protein prodynorphin and are widely distributed in the central nervous system (CNS), including the spinal cord, hippocampus, and hypothalamus (Khachaturian et al., 1982, Science). The (2-17) fragment retains significant biological activity, including the ability to activate KORs and modulate neurotransmitter release, but lacks the N-terminal tyrosine residue required for high-affinity binding to mu- and delta-opioid receptors (Wollemann & Benyhe, 2004, Eur J Pharmacol). This selectivity underpins its utility in dissecting the physiological and pathological roles of KOR signaling.

[Related: sb431542 inhibitor] Clinical Value and Applications
Dynorphin (2-17), amide, porcine, has emerged as a critical tool in the investigation of pain pathways, neurodegenerative diseases, and psychiatric disorders. Its primary clinical value lies in its ability to selectively activate KORs, thereby modulating pain perception and stress responses without the pronounced addictive potential associated with mu-opioid receptor agonists (Simonin et al., 1998, J Pharmacol Exp Ther).

In preclinical models, dynorphin (2-17) has demonstrated efficacy in attenuating neuropathic and inflammatory pain, suggesting potential therapeutic applications in chronic pain syndromes where conventional opioids are limited by tolerance and dependence (Vanderah et al., 1996, J Pharmacol Exp Ther). Additionally, KOR agonists have shown promise in reducing drug-seeking behaviors and mitigating the rewarding effects of substances such as cocaine and alcohol, positioning dynorphin (2-17) as a candidate for addiction research (Shippenberg et al., 2007, Pharmacol Ther).

[Related: NSC 693627] Beyond pain and addiction, dynorphin (2-17) is implicated in neuroprotection following ischemic injury and in the modulation of emotional states, including anxiety and depression. Its ability to influence glutamatergic and dopaminergic neurotransmission further broadens its relevance to neuropsychiatric and neurodegenerative disorders (Bruchas et al., 2010, Trends Pharmacol Sci).

Key Challenges and Pain Points Addressed
Current analgesic therapies, particularly those targeting the mu-opioid receptor, are associated with significant drawbacks, including tolerance, dependence, respiratory depression, and risk of overdose. There is a pressing need for novel analgesics that provide effective pain relief with reduced side effect profiles.

[Related: sb431542 sigma] Dynorphin (2-17), by selectively targeting KORs, offers a pathway to analgesia that circumvents many of the adverse effects of mu-opioid agonists. KOR agonists are less likely to induce euphoria and dependence, making them attractive for chronic pain management and for use in populations at risk for substance abuse (Lalanne et al., 2014, Front Pharmacol).

Another challenge in neurodegenerative and psychiatric research is the lack of specific tools to dissect the contributions of endogenous opioid systems. Dynorphin (2-17) provides a selective probe for KOR-mediated signaling, enabling researchers to delineate the roles of dynorphinergic pathways in disease models and to identify novel therapeutic targets.

Literature Review
A growing body of literature supports the utility of dynorphin (2-17) in basic and translational research:

1. **Chavkin et al. (1982, Science):** This seminal study identified dynorphin as an endogenous ligand for the KOR, demonstrating its potent inhibitory effects on neurotransmitter release in the CNS.

2. **Vanderah et al. (1996, J Pharmacol Exp Ther):** The authors showed that intrathecal administration of dynorphin (2-17) produces antinociceptive effects in rodent models of neuropathic pain, supporting its role in spinal pain modulation.

3. **Simonin et al. (1998, J Pharmacol Exp Ther):** This study characterized the pharmacological properties of dynorphin fragments, highlighting the selectivity of dynorphin (2-17) for KORs and its reduced affinity for mu- and delta-opioid receptors.

4. **Shippenberg et al. (2007, Pharmacol Ther):** The review discusses the involvement of dynorphin/KOR systems in addiction, noting that KOR activation can attenuate the rewarding effects of drugs of abuse.

5. **Bruchas et al. (2010, Trends Pharmacol Sci):** The authors review the role of KORs in stress, mood, and addiction, emphasizing the therapeutic potential of KOR-selective ligands.

6. **Lalanne et al. (2014, Front Pharmacol):** This paper explores the clinical implications of KOR agonists and antagonists, including their potential to treat pain and mood disorders with fewer side effects than traditional opioids.

7. **Wollemann & Benyhe (2004, Eur J Pharmacol):** The review provides a comprehensive overview of opioid peptide fragments, including dynorphin (2-17), and their receptor selectivity and functional roles.

Experimental Data and Results
Experimental studies have elucidated the pharmacological profile and functional effects of dynorphin (2-17), amide, porcine, in various in vitro and in vivo systems.

**Receptor Binding and Selectivity:**
Radioligand binding assays have confirmed that dynorphin (2-17) exhibits high affinity for KORs, with negligible activity at mu- and delta-opioid receptors (Simonin et al., 1998). This selectivity is attributed to the absence of the N-terminal tyrosine, which is critical for mu- and delta-receptor binding.

**Antinociceptive Effects:**
In rodent models, intrathecal or intracerebroventricular administration of dynorphin (2-17) produces dose-dependent antinociception, as measured by tail-flick and hot-plate assays (Vanderah et al., 1996). The antinociceptive effects are reversed by selective KOR antagonists, confirming receptor specificity.

**Neuroprotection and Neurotoxicity:**
While low to moderate concentrations of dynorphin (2-17) are neuroprotective in models of ischemia and excitotoxicity, higher concentrations can induce neurotoxicity via non-opioid mechanisms, including activation of NMDA receptors and promotion of excitotoxic cell death (Hauser et al., 1999, J Neurosci). This biphasic effect underscores the importance of dose optimization in experimental protocols.

**Behavioral Effects:**
Behavioral studies indicate that dynorphin (2-17) can modulate stress-induced behaviors and reduce drug-seeking in addiction models (Shippenberg et al., 2007). However, excessive KOR activation may also contribute to dysphoria and depressive-like states, highlighting the need for careful titration and context-specific application.

Usage Guidelines and Best Practices
The application of dynorphin (2-17), amide, porcine, in research settings requires adherence to established protocols to ensure reproducibility and safety.

**Preparation and Storage:**
Dynorphin (2-17) should be reconstituted in sterile water or appropriate buffer to the desired concentration. Stock solutions can be aliquoted and stored at -20°C to -80°C to prevent repeated freeze-thaw cycles, which may degrade peptide integrity.

**Dosing and Administration:**
Effective concentrations vary depending on the experimental model and route of administration. In rodent studies, doses ranging from 0.1 to 10 nmol are commonly used for intrathecal or intracerebroventricular injection (Vanderah et al., 1996). Dose-response studies are recommended to determine the optimal concentration for specific endpoints.

**Controls and Specificity:**
To confirm KOR-mediated effects, parallel experiments with selective KOR antagonists (e.g., nor-BNI) should be conducted. Inclusion of vehicle controls and, where appropriate, comparison with other opioid peptides (e.g., dynorphin A(1-17), enkephalins) can help delineate specificity.
< Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 31 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11569199